Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 23 of 23 publications.

Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Mar;21(7):833-42. doi: 10.1080/14796694.2025.2464485

Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Mar;21(7):843-51. doi: 10.1080/14796694.2025.2463276

Ailawadhi S, Inocencio TJ, Mansfield C, Chintakayala P, Bussberg C, Chi L, Harnett J, Kroog GS, Rodriguez-Lorenc K, Ma Q. Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study. Future Oncol. 2025 Mar;21(7):853-65. doi: 10.1080/14796694.2025.2461430

Passamonti F, Korgaonkar S, Parikh RC, Chevli M, Yucel A, Rombi J, Jones S, Zissler D, Davis KL, Slaff S. Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncol. 2025 Feb;21(5):579-91. doi: 10.1080/14796694.2025.2454895

Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment. Future Oncol. 2024;20(28):2059-70. doi: 10.1080/14796694.2024.2348440

Diez-Campelo M, Yucel A, Goyal RK, Parikh RC, Esterberg E, Jimenez M, Sluga-O'Callaghan M, Miteva D, Xiao H, Germing U. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe. Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228

Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024;20(22):1553-63. doi: 10.2217/fon-2023-1064

Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Derrien Ansquer V, Caro N, Saliba TR. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-28. doi: 10.2217/fon-2022-1133

DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-47. doi: 10.2217/fon-2021-0742

Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021 Jul;17(21):2759-68.

Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncol. 2021 Jun;17(17):2151-67. doi: 10.2217/fon-2020-1193

Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol. 2020 Nov;16(31):2475-85. doi: 10.2217/fon-2020-0573

Vassilev ZP, Soriano Gabarro M, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtala J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. Future Oncol. 2020 Sep;16(25):1889-901. doi: 10.2217/fon-2020-0315

Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. Future Oncol. 2019 Jan;15(2):141-50. doi: 10.2217/fon-2018-0531

Ford LB, Matz J, Hankinson T, Prillaman B, Georges G. A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis. Allergy Asthma Proc. 2015 Jul;36(4):313-9. doi: 10.2500/aap.2015.36.3860

White MV, Hogue SL, Bennett ME, Goss D, Millar K, Hollis K, Siegel PH, Wolf RA, Wooddell M, Silvia S. EpiPen4Schools pilot survey: occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting. Allergy Asthma Proc. 2015 Jul;36(4):306-12. doi: 10.2500/aap.2015.36.3859

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan;31(1):68-75. doi: 10.2500/aap.2010.31.3306

Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, Philpot EE. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009 Mar;30(2):128-38. doi: 10.2500/aap.2009.30.3204

Santanello NC, DeMuro-Mercon CJ, Shah SR, Schenkel EJ, Ratner PH, Norquist JM, Philip G. Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis. Allergy Asthma Proc. 2006 May 1;27(3):231-9.

Sheth KK, Cook CK, Philpot EE, Prillaman BA, Witham LA, Faris MA, Klein KC, Rickard KA. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc. 2004 Mar;25(2):115-20.

Allen DB, Meltzer EO, Lemanske, Jr. RF, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002 Nov;23(6):407-13.

Ratner PH, Howland, 3rd WC, Jacobs RL, Reed KD, Goode-Sellers ST, Prillaman BA, Philpot EE, Cook CK. Relief of sinus pain and pressure with fluticasone propionate aqueous nasal spray: a placebo-controlled trial in patients with allergic rhinitis. Allergy Asthma Proc. 2002 Jul;23(4):259-63.